GlassScriptPhysician profile
Jerry J Boley
NPI 1962465435
$6,482.48
in general payments reported to CMS, 2019-2025
26 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $346 · 2021: $809 · 2022: $1,111 · 2023: $956 · 2024: $1,310 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,421 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,421.10 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,347.60 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $1,093.97 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $844.88 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $694.24 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $509.02 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $291.12 | 2019-2025 | Wainua, Farxiga, Brilinta |
| Sanofi-Aventis U.S. LLC | $249.30 | 2019-2022 | |
| Pfizer INC. | $242.29 | 2019-2025 | |
| Esperion Therapeutics, INC. | $216.15 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.79 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $132.56 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $85.85 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.25 | 2019-2024 | Lifevest |
| Boston Scientific Corporation | $74.56 | 2019-2024 | Watchman Access System |
| Amarin Pharma, INC. | $60.99 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $60.96 | 2024-2025 | Wegovy |
| Glaxosmithkline, LLC. | $57.33 | 2025 | Arexvy, Shingrix |
| Actelion Pharmaceuticals US, INC. | $53.23 | 2021 | |
| Abiomed | $46.42 | 2024 | Impella |
| Lexicon Pharmaceuticals, INC. | $44.26 | 2023-2024 | Inpefa |
| Alnylam Pharmaceuticals INC. | $41.31 | 2025 | Onpattro |
| Phathom Pharmaceuticals, INC. | $32.16 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $26.15 | 2020 | |
| Inspire Medical Systems, INC. | $18.31 | 2025 | Inspire |
| Philips North America LLC | $14.00 | 2024 | (Ck4) Mcot |
| Arbor Pharmaceuticals, INC. | $13.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Boley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.